anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For patients assigned to open-label treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, open-label resmetirom at same dose as MGL-3196-14 for an additional 52 weeks. NASH cirrhosis patients may receive open-label resmetirom for an additional 52 weeks (ie, 52 weeks in MGL-3196-14 and 104 weeks in MGL-3196-18).
PURPOSE OF REVIEW: Micronutrients are vital dietary components for growth and development. Adequate intake of vitamins and minerals through diet is crucial for proper biomolecular and cellular functioning. Many developed countries supplement foods and micronutrient deficiencies are less common. However, many disease states impair micronutrient absorption, metabolism, and excretion. Thus, early recognition of the signs and symptoms of micronutrient deficiencies is critical for providers to improve quality of life and prevent complications in high-risk patients. This article reviews the basic function of micronutrients, recognizes the symptoms of each micronutrient deficiency, provides natural sources of intake, and discusses the diagnosis and supplementation of each micronutrient. High risk patients based on disease state for each micronutrient is discussed. In addition, Bariatric patients are a specific group at high risk of micronutrient deficiency and their management and supplementation for treatment is also covered.
RECENT FINDINGS: Micronutrients play a vital role in antioxidant defense, especially in critically ill patients, due to an increase in oxidative stress. Early intervention with high-dose supplementation with vitamin C, vitamin E, zinc and selenium may have beneficial effects. Micronutrients deficiency remains an issue for patients in the developed world. Providers should recognize patients who are at high risk for micronutrients deficiencies and provide proper screening and prompt supplementation after diagnosis to prevent complications of micronutrient deficiencies.
Yoga is a holistic life science with a history of approximately 5000 years, designed to prepare the individual for meditation by strengthening the body and calming the mind. Looking at the national and international literature, no study comparing the effects of traditional and artificial intelligence-based practices on quality of life and mental well-being has been found before. The aim of the study was to compare the effects of traditional yoga and artificial intelligence-supported yoga practice on quality of life and mental well-being in students in a randomized controlled trial. The population of the study consisted of approximately 880 students studying at Çanakkale Onsekiz Mart University, Faculty of Health Sciences, Departments of Nursing (n=460), Midwifery (n=310) and Emergency Aid and Disaster Management (n=110). In the study, a simple random sampling method was selected according to the literature to ensure homogeneity of the sample. With power analysis, the effect size was 0.35, the α value was 0.05, and the power was 0.90, and the number of samples was found to be 54 people in total, including 18 in the 1st intervention group, 18 in the 2nd intervention group, and 18 in the control group. The research will be collected face-to-face between February 1, 2024, and November 30, 2025, using the Introductory Information Form, Multidimensional Quality of Life Scale, and Mental Well-Being Scale. In the study, two intervention and control groups will be pre-tested. The first intervention group will receive traditional yoga practice, and the second intervention group will receive AI-supported yoga practice. The control group will not receive any intervention during the data collection process. After the interventions are completed, post-tests (Introductory Information Form, Multidimensional Quality of Life Scale, and Mental Well-Being Scale) will be applied to all three groups. In order to eliminate ethical problems in the control group, days and hours suitable for individuals will be determined after the data collection process is completed, and traditional yoga will be practiced preferably once a week for an average of 2 hours or AI-assisted yoga for 1 hour a week for 12 weeks. In this research, at the same time, while applying AI-assisted yoga to the 2nd intervention group, images will be captured with the help of Mediapipe, correct posture will be determined, the angles between the joint points will be determined and recorded, and correct posture predictions will be made with the image processing technique of artificial intelligence.
The present brow lift and freeze kit and method provides an instant brow lift without the need for surgery or Botox® injections. The kit comprises a lifting and freezing composition, an applicator, an astringent cleanser, and cotton swabs. Optionally, the kit may include adhesive strips for placing on the user's forehead and/or glabella during application of the lifting and freezing composition. The lifting and freezing composition is spread across the user's brows. The applicator is used to lift and sculpt the eyebrows into a desirable shape. The lifting and freezing composition is allowed to dry. After the drying, any excess flax seed composition above the brows is removed by dabbing with a swab wetted with astringent cleanser. Optionally, an adhesive strip may be affixed to the user's forehead and/or glabella to prevent muscle movement of the upper face during application and drying of the lifting and freezing composition.
The present invention relates to a prescription with the functions of resisting oxidation, improving cellular respiration, resisting inflammation and improving blood circulation and a preparing method thereof. Therefore, an acceptable preparation, such as soft capsules, dripping pills, liquid agents, etc., for preventing or treating cardiovascular and cerebrovascular diseases, cancer, and hyperplasia of prostate, and delaying aging can be prepared. The present invention has the technical scheme that the preparation essentially comprises effective components of 0.5 to 40% of lycopene, 7 to 50% of coenzyme Q10, 0.3 to 70% of gamma-linolenic acid and 0.3 to 70% of alpha-linolenic acid, and auxiliary materials, the effective components of the lycopene, the coenzyme Q10, the gamma-linolenic acid, the alpha-linolenic acid, etc. are prepared into the prescription according to a certain proportion, and the one-time used dose in the prepared finished product contains 2.5 to 20 mg of lycopene, 3.5 to 25 mg of coenzyme Q 10, 1.5 to 150 mg of gamma-linolenic acid and 1.5 to 150 mg of alpha-linolenic acid. Except for linoleic acid, other solvent substrates are composed of one kind or several kinds of oleic acid, linoleic acid, etc. of single and/or multiple unsaturated fatty acid, etc. of edible plant oil or medicinal oil. According to requirements, perfumery agents (such as cinnamon oil, etc.) can be added into physic liquor. The product of the present invention can be prepared into the acceptable preparations of soft capsules, dripping pills, liquid agents, etc.
The invention provides "sanhuang" heart-fire removing decoction formula granules and a preparing method and a detection method thereof. The granules are prepared by adding water into rheum officinale, root of baikal skullcap and Chinese goldthread in a weight ratio of 2:1:1, decocting, filtering, and concentrating and drying filtrate. The detection method includes: identifying the granules by a thin-layer chromatography method; detecting a fingerprint spectrum of the granules by a high performance liquid chromatography method; detecting the extract content of the granules by a hot dipping method; and detecting the contents of compounds in the granules by a high performance liquid chromatography method. The "sanhuang" heart-fire removing decoction is prepared by mixed-decoction according to traditional methods, advantages of traditional Chinese medicine compatibility are fully exerted, the holism concept of traditional Chinese medicines is reflected, and effects of toxicity reducing and efficacy enhancing are achieved. Disadvantages brought by simple addition of medicines in a taking process of single-medicine formula granules at present are overcome. Process conditions and complete quality standards of the granules are established.
Participants will receive dupilumab as per its label in period 1. Eligible participants will receive upadacitinib dose A in period 2.
Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine- 2,6-dione, 3,7-dihydro-1 ,3 –dimethyl-, and is represented by the following structural formula:

The molecular formula of anhydrous theophylline is C7H8N402 with a molecular weight of 180.17. THEOPHYLLINE ORAL SOLUTION, USP is available as a liquid intended for oral administration, containing 80 mg of theophylline anhydrous in each 15 mL (tablespoonful). 

THEOPHYLLINE ORAL SOLUTION, USP also contains the following inactive ingredients: citric acid, sodium saccharin, sodium benzoate, glycerin, propylene glycol, FD and C Red #40, natural and artificial fruity flavor and purified water. THEOPHYLLINE ORAL SOLUTION, USP has a pH of 4.0 – 5.0.
This is a multicentre, multinational, single blind, randomised and active controlled trial of intravenous ceftazidime avibactam in combination with metronidazole versus meropenem. Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before having the option to switch to an oral therapy. The decision to switch to oral therapy is entirely at the Investigator's discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food.Patients will be assessed for safety and efficacy throughout the study, and blood samples will be taken for pharmacokinetic (PK) assessment. The duration of each patient's participation in the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment (defined as the time point at which first dose of study treatment is administered) at which time there will be a late follow up (LFU) assessment visit. The LFU is to be performed 20 to 35 days after the last dose of any treatment.The assessments at the test of cure (TOC) visit should be performed in person 8 to 15 days after last dose of any study drug (IV or oral). The maximum duration of IV study drug or oral switch therapy is up to Day 15.
The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralizing antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunized with pL/YFE survived the challenge.
OBJECTIVE: The aim was to predict the effectiveness of using frailty, defined by the frailty index (FI), for predicting recurrent pneumonia and death in patients 50 years and older with vascular cognitive impairment (VCI) during long-term hospitalization.
MEASUREMENTS: This retrospective cohort study was conducted at a teaching hospital in western China and included VCI patients aged ≥50 years undergoing long-term hospitalization. The relevant data were collected from the electronic medical record system. The FI was based on 31 parameters and groups were defined using a cutoff value (0.2) as robust (FI < 0.2) and FRAIL (≥0.2). The definition of recurrent pneumonia was a minimum of two episodes within a year, with the symptoms, signs, and imaging results of pneumonia disappearing completely between episodes, and a minimum interval between episodes of seven days. Death was recorded by the hospital as the result of cardiac and respiratory arrest and survival was defined as the interval between hospital admission and confirmed death. Logistic regression models were used to assess the association between FI and recurrent pneumonia, while associations between FI and death were assessed by Cox proportional hazards models.
RESULTS: A total of 252 long-term hospitalized VCI patients ≥50 years old were enrolled, of whom 115 were male (45.6 %). Ninety-seven patients (38.5 %) were defined as FRAIL. The median length of stay for hospitalized patients was 37 months. Overall, 215 patients developed pneumonia during hospitalization, which occurred an average of 14.5 months after admission, while 151 (59.9 %) had recurrent pneumonia, and 155 (61.5 %) died. Of these, 143 died in the hospital and 12 died after discharge. No significant differences were seen in the incidence of recurrent pneumonia between FRAIL and robust long-term hospitalized VCI patients (FRAIL vs. robust: 66.0 % vs. 56.1 %, P = 0.121) while FRAIL patients had a higher mortality rate than robust patients (FRAIL vs. robust: 71.1 % vs. 55.5 %, P = 0.013). After further Cox regression analysis and adjustment for possible confounders found to be significant in the univariate analysis (including age, sex, smoking history, and activities of daily living (ADL) score), FRAIL patients had a higher risk of death than healthy patients (HR = 1.595, 95 % CI: 1.149-2.213). In addition, based on Model 2, confounding variables that were not statistically significant in the univariate analysis but may have had an impact on the results (including marital status, educational level, drinking history, comorbidity and rehabilitation treatment) were incorporated into Model 3 for further correction. The result remained unchanged, namely, that compared with robust patients, FRAIL patients had a higher risk of death (HR = 1.771, 95 % CI: 1.228-2.554).
CONCLUSIONS AND IMPLICATIONS: Frailty defined by the FI was effective for predicting the risk of mortality but not that of recurrent pneumonia in long-term hospitalized VCI patients aged 50 or older.
A boy with nonambulatory Duchenne muscular dystrophy (DMD) tested positive for exon 63 duplication and exhibited intellectual disability, overweight and dyslipidaemia. The patient underwent a comprehensive multidisciplinary approach involving pharmacological and non-pharmacological interventions. Despite challenges, such as socioeconomic constraints and limited access to advanced therapies, the patient received tailored care. The management included prednisone medication, dietary modifications and psychological support. The patient's journey highlighted the complex interplay of medical and psychosocial factors affecting DMD patients in resource-limited settings. Regular monitoring and the involvement of the patient's family in a peer group were arranged to improve overall quality of life. The case underscores the need for accessible and holistic care for DMD patients, addressing both medical and psychosocial challenges.
CR is identical to the one described under the Active Comparator Arm. However, sham tDCS will consist of active stimulation for only 1 min/day, at the beginning of each group session. tDCS montage and the frequency of the sessions and the boosters will be the same as for the Active Arm.
PURPOSE:To obtain a solid powdery cosmetic having excellent applicability to the skin and capable of accurately forming an arbitrary formed article having complicate shape in a short time, by kneading a powdery cosmetic containing a water-soluble polymeric compound with water, filling the mixture in a mold and solidifying and drying the mixture in a freeze-drier. CONSTITUTION:A powdery raw material is mixed thoroughly with a water-soluble polymeric compound and water and the mixture is filled in a forming mold. The mold is put into a freeze-drier and quenched from room temperature to <=-40 deg.C. The space in the freeze-drier or the mixture in the forming mold may be cooled to frozen state before putting the mold into the freeze-drier. The mixture is dried in vacuum while raising the temperature of the freeze-drier to obtain the objective powdery cosmetic having a complicate shape in a short time compared with conventional method. The obtained cosmetic can be removed easily from the brush, etc., and has excellent spreadability and applicability to the skin. The amount of the polymeric compound is preferably 0.05-5.0wt% based on the mixture and that of water preferably 10-250pts.wt. per 100pts.wt. of the produced formed cosmetic.
Considering the high prevalence and poor prognosis of cardiometabolic multimorbidity (CMM), identifying causal factors and actively implementing preventive measures is crucial. However, Mendelian randomization (MR), a key method for identifying the causal factors of CMM, requires knowledge of the effects of SNPs on CMM, which remain unknown. We first analyzed the genetic overlap of single cardiometabolic diseases (CMDs) using the latest genome-wide association study (GWAS) for evidential support and comparison. We observed strong positive genetic correlations and shared loci among all CMDs. Further, GWAS and post-GWAS analyses of CMM were performed in 407 949 European ancestry individuals from the UK Biobank. Eleven loci and 12 lead SNPs were identified. By comparison, we found these SNPs were a subset of SNPs associated with CMDs, including both shared and non-shared SNPs. Then, the polygenic risk score model predicted the risk of CMM (C-index = 0.62) and we identified candidate genes related to lipid metabolism and immune function. Finally, as an example, two-sample MR analysis based on the GWAS revealed potential causal effects of total cholesterol, serum urate, body mass index, and smoking on CMM. These results provide a basis for future MR research and inspire future studies on the mechanism and prevention of CMM.
Osteoarthritis of the thumb carpometacarpal joint is a common condition that affects approximately 16% to 25% of postmenopausal woman and causes pain, swelling, instability, deformity and loss of motion. This condition has been staged in 4 periods according to the degree of severity. Mild stages or stages 1 and 2 are usually treated conservatively by stabilization of the joint, which can be aggressively achieved by surgical ligament reconstruction or conservatively with thumb splints. Splinting is a typical treatment for osteoarthritis of the thumb with the goals of managing pain, stabilizing the CMC joint, and improving overall thumb function. There are limited studies showing the effectiveness of splinting for this condition indicating they are successful in decreasing pain and improving function in activities of daily living as well as radiographically improving joint stability. What is less clear is, once patients leave the clinic setting, how compliant they are with their splinting regimen. Patients with chronic illnesses tend to have compliance issues when it comes to their care. Also, there are limited studies comparing different modalities of splinting. A recent study compared custom-made short opponens thermoplastic splint with the metacarpo-phalangeal (MP) joint free to a pre-fabricated short neoprene splint. They found that patients preferred the neoprene splint but both splints provided some degree of pain relief, reduction of subluxation of the MP joint and improvement in function. Our purpose is to objectively quantify the various benefits of splinting for patients with thumb arthritis using the DASH score and assess if there is a difference between the pre-fabricated neoprene splint and the custom-made short opponens thermoplastic splint with the MP included.
BACKGROUND: The purpose of this study was to establish consensus statements via a modified Delphi process on the definition of shoulder pseudoparalysis and pseudoparesis.
METHODS: A consensus process on the definition of a diagnosis of pseudoparalysis utilizing a modified Delphi technique was conducted, and 26 shoulder/sports surgeons from 11 countries, selected based on their level of expertise in the field, participated in these consensus statements. Consensus was defined as achieving 80%-89% agreement, whereas strong consensus was defined as 90%-99% agreement, and unanimous consensus was indicated by 100% agreement with a proposed statement.
RESULTS: Three statements regarding the diagnosis of pseudoparalysis reached strong (>89%) consensus: passive range of motion should be unaffected, the passive range of abduction should not be considered, and diagnosis should be excluded if lidocaine injection produces a substantial improvement in range of motion. Additionally, consensus (>79%) was reached that the active range of external rotation should not be considered for diagnosis, pain as a cause of restricted motion must be excluded, and that distinctions between restricted active flexion and external rotation should be made by range of motion rather than tear characteristics. No consensus could be reached on statements regarding the size, number of tendons or chronicity of cuff tears. Nor was there agreement on the active range of flexion permitted or on the difference between pseudoparalysis and pseudoparesis.
CONCLUSION: A modified Delphi process was utilized to establish consensus on the definition of shoulder pseudoparalysis and pseudoparesis. Unfortunately, almost half of the statements did not reach consensus, and agreement could not be reached across all domains for a unifying definition for the diagnosis of pseudoparalysis in the setting of rotator cuff tears. Furthermore, it was not agreed how or whether pseudoparalysis should be differentiated from pseudoparesis. Based on the lack of a consensus for these terms, studies should report explicitly how these terms are defined when they are used.
Sodium bicarbonate 8.4% (1000 mEq/L) will be diluted in a D5W solution (500 mL bag). For preparation, 300 mL of D5W will be removed and 300 mL of sodium bicarbonate 8.4% added to prepare the bicarbonate solution in a total volume of 500 mL (final concentration: 600 mEq/L).
This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participants with HbA1c levels between 6.5-8.9% (inclusive) will be recruited and randomized into either the placebo or intervention group. The study duration for each participant will be approximately 90 days. At the beginning of the 90 days, the participant will complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome. After the samples are analyzed, the participant will receive dietary recommendations and either personalized supplements or placebo supplements. The participant will follow the dietary recommendations and take the supplements for 90 days. At the end of the 90 days, the participant will once again complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome for analysis.
Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.